These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 25731247

  • 1. [A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
    Takeda Y, Nakahira S, Katsura Y, Ohmura Y, Kusama H, Kuroda Y, Goto T, Hashimoto T, Kimura K, Matsushita K, Sato Y, Morimoto Y, Ishida T, Nitta K, Kagawa Y, Okishiro M, Takeno A, Sakisaka H, Taniguchi H, Egawa C, Ohzono K, Nakatsuka S, Kato T, Tamura S.
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1545-7. PubMed ID: 25731247
    [Abstract] [Full Text] [Related]

  • 2. [A case of drug resistant recurrent gastrointestinal stromal tumor treated surgically by resection, partial hepatectomy and diaphragmectomy].
    Ueda N, Morioka E, Kaida D, Tomita Y, Ohnishi T, Ohno Y, Noguchi M, Funaki H, Kinami S, Omote K, Nakano Y, Kosaka T, Nakata S, Minato H, Takamura H.
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2438-40. PubMed ID: 23268103
    [Abstract] [Full Text] [Related]

  • 3. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
    [No Abstract] [Full Text] [Related]

  • 4. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T, Doi T, Naito Y.
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [Abstract] [Full Text] [Related]

  • 5. [A case of imatinib-resistant GIST treated by sunitinib].
    Sakamoto Y, Akimoto H, Kojo M, Kawano H, Chinen Y, Morita K, Sugiyama M, Saeki H, Minami K, Soejima Y, Sakaguchi Y, Toh Y, Okamura T.
    Gan To Kagaku Ryoho; 2011 May; 38(5):827-30. PubMed ID: 21566447
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L.
    Drug Des Devel Ther; 2014 May; 8():2061-7. PubMed ID: 25378911
    [Abstract] [Full Text] [Related]

  • 7. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
    Kikuchi H, Setoguchi T, Miyazaki S, Yamamoto M, Ohta M, Kamiya K, Sakaguchi T, Konno H.
    Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
    Son MK, Ryu MH, Park JO, Im SA, Kim TY, Lee SJ, Ryoo BY, Park SR, Kang YK.
    Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
    [Abstract] [Full Text] [Related]

  • 9. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano A, Cioffi A, Coco P, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay JY, Casali P, Keohan ML, Toulmonde M, Antonescu CR, Debiec-Rychter M, Coindre JM, Bui B.
    Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, GRID study investigators.
    Lancet; 2013 Jan 26; 381(9863):295-302. PubMed ID: 23177515
    [Abstract] [Full Text] [Related]

  • 11. [Successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for imatinib mesylate].
    Sakakura C, Kumano T, Mizuta Y, Yamaoka N, Sagara Y, Hagiwara A, Otsuji E.
    Gan To Kagaku Ryoho; 2007 Nov 26; 34(12):2144-6. PubMed ID: 18219926
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.
    J Clin Oncol; 2012 Jul 01; 30(19):2401-7. PubMed ID: 22614970
    [Abstract] [Full Text] [Related]

  • 13. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A, Boglione A.
    Recenti Prog Med; 2015 Jan 01; 106(1):17-22. PubMed ID: 25621775
    [Abstract] [Full Text] [Related]

  • 14. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
    Lyseng-Williamson KA.
    BioDrugs; 2013 Oct 01; 27(5):525-31. PubMed ID: 23975637
    [Abstract] [Full Text] [Related]

  • 15. [Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
    Liang H.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr 01; 17(4):309-11. PubMed ID: 24760634
    [Abstract] [Full Text] [Related]

  • 16. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ, Keisler MD, Walko CM.
    Ann Pharmacother; 2013 Dec 01; 47(12):1685-96. PubMed ID: 24259629
    [Abstract] [Full Text] [Related]

  • 17. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
    Murray M, Hatcher H, Jessop F, Williams D, Carroll N, Bulusu R, Judson I.
    Pediatr Blood Cancer; 2008 Feb 01; 50(2):386-8. PubMed ID: 17729245
    [Abstract] [Full Text] [Related]

  • 18. [Long-term progression-free survival after reduction surgery and postoperative low-dose imatinib administration for multiple liver metastases of duodenal gastrointestinal stromal tumor].
    Nishitai R, Manaka D, Uehara M, Hamasu S, Konishi S, Sakamoto K, Yoshino K, Kanto S, Yokoyama D, Kobayashi A, Jinzai Y, Yasuhara Y.
    Gan To Kagaku Ryoho; 2012 Jun 01; 39(6):979-82. PubMed ID: 22705697
    [Abstract] [Full Text] [Related]

  • 19. [A long-term survival case with multiple liver metastases from duodenal gastrointestinal stromal tumor that was drastically reduced by the treatment with imatinib].
    Sakakura C, Miyagawa K, Fukuda K, Kin S, Nakase Y, Kuriu Y, Nakashima S, Yoshikawa T, Yamaoka N, Sagara Y, Hagiwara A, Yamagishi H.
    Gan To Kagaku Ryoho; 2005 Oct 01; 32(11):1739-41. PubMed ID: 16315926
    [Abstract] [Full Text] [Related]

  • 20. [A case of hepatectomy for gastrointestinal stromal tumor with multiple liver metastasis after size reduction in a Jehovah's Witness patient].
    Kikutake T, Kawamoto S, Yoshida T.
    Gan To Kagaku Ryoho; 2012 Nov 01; 39(12):2015-7. PubMed ID: 23267961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.